Loading
Every dated change on the records linked to Paediatric high-grade glioma (excluding diffuse midline glioma), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Dabrafenib plus trametinib (paediatric high-grade glioma cohort 2023; tumour-agnostic approval for BRAF V600E solid tumours from age six).
A milestone in how this cancer is treated.
Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.
Grill and colleagues (JCO).